AKT1 and cancer: Moreover, pharmacological FGFR4 targeting specifically sensitized the cells, in addition to HER2/EGFR and PI3K/AKT/mTOR inhibitors, to the modulators of mitochondrial apoptosis pathway, suggesting interesting possibilities also for combinatorial treatments to effectively halt the FGFR4+/HER2+ cancers [63].